RSS

Category Archives: symptoms

See the Signs of Alzheimer’s– Free Guide Available

This free guide is an excellent resource and should be especially interesting to baby boomers. The guide includes: information about Alzheimer’s disease, information about a prescription treatment option, a doctor discussion guide, and caregiving tips.

While you are on the website obtaining this free resource guide you can also select an option that allows a caregiving nurse to call you and discuss Alzheimer’s topics. The nurse can help you identify issues to discuss with your doctor, answer questions about Alzheimer’s, and provide you with important tips and resources in your area.

To obtain this free material go to See The Signs.

You can also visit these interesting areas while you are on the website.

Signs & Symptoms

Symptom Screener

Original content the Alzheimer’s Reading Room

Amazon.com Widgets

Advertisements
 

Most Early Onset Dementia Not Alzheimer’s

“This is really a novel finding, because there hasn’t really been a study that’s looked at young-onset dementia in this way,” said study author Dr. Brendan J. Kelley, a neurologist at the Mayo Clinic in Rochester, Minn. “And the message is that young-onset dementia is generally not related to Alzheimer’s.”

For a more detailed report on early-onset Alzheimer’s, visit the U.S. Administration on Aging.

HealthDay News — The root cause of early-onset dementia is usually not Alzheimer’s, but rather another neurodegenerative or autoimmune disorder, new research suggests.

The study authors acknowledge that — age aside — the most common forms of dementia are Alzheimer’s disease, vascular dementia and the brain damage-associated condition known as Lewy body dementia. However, their current work indicates that among patients below the age of 45, the problem is much more likely to be traced back to diseases such as multiple sclerosis, Huntington’s, lupus or HIV infection, among others.

“This is really a novel finding, because there hasn’t really been a study that’s looked at young-onset dementia in this way,” said study author Dr. Brendan J. Kelley, a neurologist at the Mayo Clinic in Rochester, Minn. “And the message is that young-onset dementia is generally not related to Alzheimer’s.”

The work of Kelley and his team was expected to be presented April 15 at the American Academy of Neurology annual meeting, in Chicago.

The U.S. Administration on Aging highlights 2006 estimates released by the Alzheimer’s Association, which indicate that between 220,000 and 640,000 American men and women currently suffer from early-onset dementia. The association specifically defines “early-onset Alzheimer’s” as referring to cases that develop before the age of 65.

However, in their study, Kelley and his team focused exclusively on 235 patients diagnosed with a form of dementia diagnosed between the ages of 17 and 45 — citing statistics suggesting that 12 in 100,000 people develop some form of early-onset dementia before the age of 45.

All the study patients had sought care at the Mayo Clinic between 1996 and 2006, and all had normal cognitive function prior to their dementia diagnosis.

A medical record analysis revealed that despite the fact that most adult dementia is a function of Alzheimer’s, less than 2 percent of the cases among the under-45 group was attributable to that disease.

Kelley and his colleagues found that other neurodegenerative conditions — such as frontotemporal dementia, a group of diseases commonly misdiagnosed as Alzheimer’s — were at play in almost one-third of the cases.

Autoimmune and inflammatory disorders — such as MS — accounted for just over 20 percent of the dementia cases. Metabolic abnormalities were cited in just over 10 percent of the diagnoses, while for another 20 percent, no cause for dementia could be established.

Kelley said his work is ongoing. And he added that he and his colleagues are now trying to identify specific disease markers for early-onset dementia to help physicians distinguish those cases prompted by causes other than Alzheimer’s.

“Because some of the other disorders linked to early dementia have treatable profiles that allow targeting not just of the symptoms but of the underlying disease process,” he noted. “So, we really should be looking to identify them quickly when they are the cause, because the research suggests that treatment could result in a direct improvement of the patient’s cognition and behavior.”

Greg M. Cole, associate director of the Alzheimer’s Disease Research Center at the UCLA David Geffen School of Medicine, described the findings as “interesting, but not completely unexpected”.

“We know that Alzheimer’s gets rarer and rarer the younger you go,” he said. “So, when you’re focused as this study is on people between 17 and 45 — really before middle-age — it’s more likely you’ll find some other cause for the dementia, which can be a variety of different things.”

“But if you’re looking at these other autoimmune causes — multiple sclerosis, lupus, HIV — the real question is, can you treat any of this?,” pondered Cole. “Because you can get lupus and MS to go into remission. So, in this case, if patients are getting dementia caused by either disease, can the dementia also go into remission? If they can get that to happen, that would be very interesting.”

More information

For additional information on early-onset Alzheimer’s, visit the U.S. Administration on Aging.

 

Teva can’t yet sell Alzheimer’s generic (Aricept)

My mother takes Aricept at a cost of about $160 a month. A generic versions of Aricept is sure to benefit millions and dramatically cut the cost of health care.

We use to pay over $100 a month for Zocor. The generic now runs $10 a month (since July 2007).

Drug developer Teva Pharmaceutical Industries Ltd. said Friday a U.S. District Court ordered Teva to tentatively refrain from selling a generic version of Eisai Co.’s Alzheimer’s treatment Aricept.

The tentative injunction by the U.S. District Court for the District of New Jersey was requested by Japan’s Eisai as part of an ongoing lawsuit with Teva.

Teva has already gained tentative Food and and Drug Administration approval for the generic drug and could receive final approval April 26, when the mandatory stay of approval under the patent lawsuit expires. A trial date has not yet been set.

  blog it

 

How is Alzheimer’s Disease Diagnosed?

clipped from www.nia.nih.gov

Today, the only definite way to diagnose AD is to find out whether there are plaques and tangles in brain tissue.

At specialized centers, doctors can diagnose AD correctly up to 90 percent of the time. Doctors use several tools to diagnose “probable” AD, including:

  • questions about the person’s general health, past medical problems, and ability to carry out daily activities;
  • tests to measure memory, problem solving, attention, counting, and language;
  • medical tests – such as tests of blood, urine, or spinal fluid; and
  • brain scans.
  • Why is early diagnosis important?

    An early, accurate diagnosis of AD helps patients and their families plan for the future. It gives them time to discuss care options while the patient can still take part in making decisions. Early diagnosis also offers the best chance to treat the symptoms of the disease.

    The course the disease takes and how fast changes occur vary from person to person.

      blog it

     

    Free Online Publications Alzheimer’s and Caregiving

      blog it

     

    National Institute on Aging Clinical Trials

    clipped from www.nia.nih.gov

    The Alzheimer’s Disease Clinical Trials Database is a joint project of the U.S. Food and Drug Administration (FDA) and the National Institute on Aging (NIA) maintained by the NIA’s Alzheimer’s Disease Education and Referral (ADEAR) Center.

    Here you can search a database of clinical trials on Alzheimer’s disease and dementia currently in progress at sites throughout the U.S.:

    Search for Trials 

    Trials in the News 

    More Information:

  • AD Clinical Trials: Questions & Answers
  • To search further listings of clinical trials underway at the National Institutes of Health and other research institutions, go to Clinicaltrials.gov.
  • For information about submitting a clinical trial to the ADEAR database, send an e-mail to: trials@alzheimers.org.
  • To receive updates about new clinical trials, subscribe to e-mail alerts.
  •   blog it

     

    Study Finds Improved Cognitive Health among Older Americans

    clipped from www.nia.nih.gov

    Study Finds Improved Cognitive Health among Older Americans

    Rates of cognitive impairment among older Americans are on the decline, according to a new study supported by the National Institutes of Health (NIH) comparing the cognitive health of older people in 1993 and 2002. Higher levels of education were associated with better cognitive health.

      blog it

     
     
    %d bloggers like this: